However, whether dual-target CAR T cells targeting both FLT3 and NKG2D are effective and whether the combination of an FLT3 inhibitor and these bispecific FLT3 single-chain fragment variable (scFv)/NKG2D-CAR T cells can induce a synergistic anti-AML effect have not been assessed. Here, FLT3 is linked to acute myeloid leukemia.